TapewireFind a company

person · Reporting owner

Dearen Danny L.

Disclosed activity across 3 companies

Tapewire entity
44223
SEC CIK
0001756438

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Beta Bionics, Inc.BBNX · Entity 2350DirectorMay 21, 2026May 26, 2026
InspireMD, Inc.NSPR · Entity 7318DirectorJanuary 14, 2026January 16, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Beta Bionics, Inc.

Report date May 21, 2026 · Filed May 26, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect32,209 Reported balance After 2026-05-21 transaction · row 1
1 source row

Row 1 · 2026-05-21 · Grant · Acquired 16,965 · Balance 32,209

F1: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

InspireMD, Inc.

Report date January 14, 2026 · Filed January 16, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect102,047 Reported balance After 2026-01-14 transaction · row 1
1 source row

Row 1 · 2026-01-14 · Grant · Acquired 44,030 · Balance 102,047

F1: These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Axonics, Inc.

Report date September 29, 2023 · Filed October 03, 2023

Section 16 reporting ended · disclosed 2023-10-03. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect23,777 Ending reported balance After 2023-09-29 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2023-09-29 · Exercise / conversion · Acquired 11,250 · Balance 31,452

Row 2 · 2023-09-29 · Sale · Disposed 7,675 · Balance 23,777

F1: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F2: This transaction was executed in multiple trades at prices ranging from $56.51 to $57.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2023-09-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2023-09-29 · Exercise / conversion · Disposed 11,250 · Balance 0

F3: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023. The units represented here are pro-rated through the date of separation.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F2: This transaction was executed in multiple trades at prices ranging from $56.51 to $57.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023. The units represented here are pro-rated through the date of separation.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 21, 2021 Filed Apr 23, 2021 19:50 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 8,046 $62.15 $500,056.49
Disclosure

SEC source: 0001562180-21-002932 · primarydocument.xml · nonDerivative · entry 8

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F6 · price: This transaction was executed in multiple trades at prices ranging from $62.00 to $62.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 21, 2021 Filed Apr 23, 2021 19:50 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 14,382 $61.58 $885,693.90
Disclosure

SEC source: 0001562180-21-002932 · primarydocument.xml · nonDerivative · entry 7

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,046

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F5 · price: This transaction was executed in multiple trades at prices ranging from $61.00 to $61.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 21, 2021 Filed Apr 23, 2021 19:50 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 2,572 $60.30 $155,082.34
Disclosure

SEC source: 0001562180-21-002932 · primarydocument.xml · nonDerivative · entry 6

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,428

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $60.00 to $60.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 21, 2021 Filed Apr 23, 2021 19:50 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 15,103 $14.19 $214,311.57
Disclosure

SEC source: 0001562180-21-002932 · primarydocument.xml · nonDerivative · entry 5

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 21, 2021 Filed Apr 23, 2021 19:50 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 9,897 $1.42 $14,053.74
Disclosure

SEC source: 0001562180-21-002932 · primarydocument.xml · nonDerivative · entry 4

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,897

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 20, 2021 Filed Apr 23, 2021 19:50 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 1,265 $0.00 Strike: $1.42 $0.00
Disclosure

SEC source: 0001562180-21-002932 · primarydocument.xml · derivative · entry 9

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,615

Underlying: Common Stock · 1,265 shares

Expires 2027-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on July 21, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of July 21, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
April 20, 2021 Filed Apr 23, 2021 19:50 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 1,769 $58.61 $103,688.34
Disclosure

SEC source: 0001562180-21-002932 · primarydocument.xml · nonDerivative · entry 3

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F3 · price: This transaction was executed in multiple trades at prices ranging from $58.585 to $58.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 20, 2021 Filed Apr 23, 2021 19:50 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 73,231 $58.14 $4,257,730.89
Disclosure

SEC source: 0001562180-21-002932 · primarydocument.xml · nonDerivative · entry 2

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,769

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $57.585 to $58.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 20, 2021 Filed Apr 23, 2021 19:50 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 1,265 $1.42 $1,796.30
Disclosure

SEC source: 0001562180-21-002932 · primarydocument.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 01, 2021 Filed Feb 2, 2021 20:51 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionPerformance-Based Restricted Stock Units · Derivative 8,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-21-000758 · primarydocument.xml · derivative · entry 7

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2020, and provided the reporting person remains in continuous service through January 30, 2021. The awards were earned at 200% of the target number on January 31, 2021.

F1 · derivative.exercise_price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2020, and provided the reporting person remains in continuous service through January 30, 2021. The awards were earned at 200% of the target number on January 31, 2021.

F1 · derivative.exercise_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2020, and provided the reporting person remains in continuous service through January 30, 2021. The awards were earned at 200% of the target number on January 31, 2021.

F1 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2020, and provided the reporting person remains in continuous service through January 30, 2021. The awards were earned at 200% of the target number on January 31, 2021.

Read SEC document
February 01, 2021 Filed Feb 2, 2021 20:51 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 507 $52.12 $26,423.78
Disclosure

SEC source: 0001562180-21-000758 · primarydocument.xml · nonDerivative · entry 4

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,735

F2 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F4 · price: This transaction was executed in multiple trades at prices ranging from $52.04 to $52.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 01, 2021 Filed Feb 2, 2021 20:51 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 6,751 $51.36 $346,761.74
Disclosure

SEC source: 0001562180-21-000758 · primarydocument.xml · nonDerivative · entry 3

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,242

F2 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F3 · price: This transaction was executed in multiple trades at prices ranging from $51.03 to $52.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 01, 2021 Filed Feb 2, 2021 20:51 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 16,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-21-000758 · primarydocument.xml · nonDerivative · entry 2

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,993

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2020, and provided the reporting person remains in continuous service through January 30, 2021. The awards were earned at 200% of the target number on January 31, 2021.

Read SEC document
January 31, 2021 Filed Feb 2, 2021 20:51 UTC Axonics, Inc. AXNX · Entity 86004 GrantPerformance-Based Restricted Stock Units · Derivative 10,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-21-000758 · primarydocument.xml · derivative · entry 6

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires not disclosed

F6 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2023, and provided the reporting person remains in continuous service through January 31, 2023.

F6 · derivative.exercise_price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2023, and provided the reporting person remains in continuous service through January 31, 2023.

F6 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2023, and provided the reporting person remains in continuous service through January 31, 2023.

Read SEC document
January 31, 2021 Filed Feb 2, 2021 20:51 UTC Axonics, Inc. AXNX · Entity 86004 GrantPerformance-Based Restricted Stock Units · Derivative 10,833 $0.00 $0.00
Disclosure

SEC source: 0001562180-21-000758 · primarydocument.xml · derivative · entry 5

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,833

Underlying: Common Stock · 10,833 shares

Expires not disclosed

F5 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2021 and provided the reporting person remains in continuous service through January 31, 2022.

F5 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2021 and provided the reporting person remains in continuous service through January 31, 2022.

F5 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2021 and provided the reporting person remains in continuous service through January 31, 2022.

Read SEC document
January 31, 2021 Filed Feb 2, 2021 20:51 UTC Axonics, Inc. AXNX · Entity 86004 GrantCommon Stock 10,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-21-000758 · primarydocument.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,993

Read SEC document
January 26, 2021 Filed Jan 27, 2021 20:08 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionPerformance-Based Restricted Stock Units · Derivative 13,043 $0.00 $0.00
Disclosure

SEC source: 0001562180-21-000566 · primarydocument.xml · derivative · entry 3

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,043 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2020 and provided the reporting person remains in continuous service through December 31, 2020.

F1 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2020 and provided the reporting person remains in continuous service through December 31, 2020.

F1 · derivative.exercise_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2020 and provided the reporting person remains in continuous service through December 31, 2020.

F1 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2020 and provided the reporting person remains in continuous service through December 31, 2020.

Read SEC document
January 26, 2021 Filed Jan 27, 2021 20:08 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 4,541 $53.58 $243,291.34
Disclosure

SEC source: 0001562180-21-000566 · primarydocument.xml · nonDerivative · entry 2

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,993

F2 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F3 · price: This transaction was executed in multiple trades at prices ranging from $53.14 to $53.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
January 26, 2021 Filed Jan 27, 2021 20:08 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 13,043 $0.00 $0.00
Disclosure

SEC source: 0001562180-21-000566 · primarydocument.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,534

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2020 and provided the reporting person remains in continuous service through December 31, 2020.

Read SEC document
July 07, 2020 Filed Jul 9, 2020 18:22 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 709 $0.00 Strike: $1.63 $0.00
Disclosure

SEC source: 0001562180-20-005090 · primarydocument.xml · derivative · entry 3

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,796

Underlying: Common Stock · 709 shares

Expires 2028-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on March 30, 2018, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of March 30, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
July 07, 2020 Filed Jul 9, 2020 18:22 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 709 $40.00 $28,360.00
Disclosure

SEC source: 0001562180-20-005090 · primarydocument.xml · nonDerivative · entry 2

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,491

F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on March 23, 2020.

Read SEC document
July 07, 2020 Filed Jul 9, 2020 18:22 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 709 $1.63 $1,155.67
Disclosure

SEC source: 0001562180-20-005090 · primarydocument.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 22, 2020 Filed Jun 22, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 8,890 $0.00 Strike: $1.32 $0.00
Disclosure

SEC source: 0001562180-20-004628 · primarydocument.xml · derivative · entry 12

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,177

Underlying: Common Stock · 8,890 shares

Expires 2027-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on July 5, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of July 5, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
June 22, 2020 Filed Jun 22, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 2,015 $0.00 Strike: $1.42 $0.00
Disclosure

SEC source: 0001562180-20-004628 · primarydocument.xml · derivative · entry 11

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,880

Underlying: Common Stock · 2,015 shares

Expires 2027-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on July 21, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of July 21, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
June 22, 2020 Filed Jun 22, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 34,095 $0.00 Strike: $1.63 $0.00
Disclosure

SEC source: 0001562180-20-004628 · primarydocument.xml · derivative · entry 10

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,505

Underlying: Common Stock · 34,095 shares

Expires 2028-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on March 30, 2018, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of March 30, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
June 22, 2020 Filed Jun 22, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 45,000 $38.11 $1,714,977.00
Disclosure

SEC source: 0001562180-20-004628 · primarydocument.xml · nonDerivative · entry 7

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,491

F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on March 23, 2020.

Read SEC document
June 22, 2020 Filed Jun 22, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 34,095 $1.63 $55,574.85
Disclosure

SEC source: 0001562180-20-004628 · primarydocument.xml · nonDerivative · entry 6

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 22, 2020 Filed Jun 22, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 8,890 $1.32 $11,734.80
Disclosure

SEC source: 0001562180-20-004628 · primarydocument.xml · nonDerivative · entry 5

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,396

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 22, 2020 Filed Jun 22, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 2,015 $1.42 $2,861.30
Disclosure

SEC source: 0001562180-20-004628 · primarydocument.xml · nonDerivative · entry 4

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,506

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 18, 2020 Filed Jun 22, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 2,251 $0.00 Strike: $1.32 $0.00
Disclosure

SEC source: 0001562180-20-004628 · primarydocument.xml · derivative · entry 9

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,067

Underlying: Common Stock · 2,045 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on July 5, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of July 5, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
June 18, 2020 Filed Jun 22, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 27,749 $0.00 Strike: $1.42 $0.00
Disclosure

SEC source: 0001562180-20-004628 · primarydocument.xml · derivative · entry 8

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,895

Underlying: Common Stock · 27,749 shares

Expires 2027-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on July 21, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of July 21, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
June 18, 2020 Filed Jun 22, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 30,000 $39.26 $1,177,881.00
Disclosure

SEC source: 0001562180-20-004628 · primarydocument.xml · nonDerivative · entry 3

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,491

F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on March 23, 2020.

Read SEC document
June 18, 2020 Filed Jun 22, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 2,251 $1.32 $2,971.32
Disclosure

SEC source: 0001562180-20-004628 · primarydocument.xml · nonDerivative · entry 2

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 18, 2020 Filed Jun 22, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 27,749 $1.42 $39,403.58
Disclosure

SEC source: 0001562180-20-004628 · primarydocument.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,240

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 19, 2020 Filed May 19, 2020 21:01 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 5,222 $0.00 Strike: $1.32 $0.00
Disclosure

SEC source: 0001562180-20-003766 · primarydocument.xml · derivative · entry 13

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,318

Underlying: Common Stock · 5,222 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on July 5, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of July 5, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
May 19, 2020 Filed May 19, 2020 21:01 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 9,778 $0.00 Strike: $1.32 $0.00
Disclosure

SEC source: 0001562180-20-003766 · primarydocument.xml · derivative · entry 12

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,317

Underlying: Common Stock · 9,778 shares

Expires 2027-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on May 23, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of May 23, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
May 19, 2020 Filed May 19, 2020 21:01 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 15,000 $40.05 $600,777.00
Disclosure

SEC source: 0001562180-20-003766 · primarydocument.xml · nonDerivative · entry 8

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,491

F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on March 23, 2020.

F5 · price: This transaction was executed in multiple trades at prices ranging from $40 to $40.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 19, 2020 Filed May 19, 2020 21:01 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 15,000 $1.32 $19,800.00
Disclosure

SEC source: 0001562180-20-003766 · primarydocument.xml · nonDerivative · entry 7

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 18, 2020 Filed May 19, 2020 21:01 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $1.32 $0.00
Disclosure

SEC source: 0001562180-20-003766 · primarydocument.xml · derivative · entry 11

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,095

Underlying: Common Stock · 15,000 shares

Expires 2027-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on May 23, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of May 23, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
May 18, 2020 Filed May 19, 2020 21:01 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 15,000 $37.26 $558,841.50
Disclosure

SEC source: 0001562180-20-003766 · primarydocument.xml · nonDerivative · entry 6

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,491

F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on March 23, 2020.

F4 · price: This transaction was executed in multiple trades at prices ranging from $37.00 to $37.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 18, 2020 Filed May 19, 2020 21:01 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 15,000 $1.32 $19,800.00
Disclosure

SEC source: 0001562180-20-003766 · primarydocument.xml · nonDerivative · entry 5

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2020 Filed May 19, 2020 21:01 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 2,722 $0.00 Strike: $1.32 $0.00
Disclosure

SEC source: 0001562180-20-003766 · primarydocument.xml · derivative · entry 10

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,095

Underlying: Common Stock · 2,722 shares

Expires 2027-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on May 23, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of May 23, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
May 15, 2020 Filed May 19, 2020 21:01 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 27,278 $0.00 Strike: $0.98 $0.00
Disclosure

SEC source: 0001562180-20-003766 · primarydocument.xml · derivative · entry 9

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,278 shares

Expires 2026-01-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares subject to the option vest over a period of four years. 34,346 of the shares subject to the option vested on January 15, 2016 and the remainder vest at a rate of 1/36th per month commencing on January 15, 2017 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
May 15, 2020 Filed May 19, 2020 21:01 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 15,000 $35.24 $528,550.50
Disclosure

SEC source: 0001562180-20-003766 · primarydocument.xml · nonDerivative · entry 4

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,491

F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on March 23, 2020.

F3 · price: This transaction was executed in multiple trades at prices ranging from $35.00to $35.455. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 15, 2020 Filed May 19, 2020 21:01 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 15,000 $35.03 $525,442.50
Disclosure

SEC source: 0001562180-20-003766 · primarydocument.xml · nonDerivative · entry 3

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,491

F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on March 23, 2020.

F2 · price: This transaction was executed in multiple trades at prices ranging from $34.58 to $35.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 15, 2020 Filed May 19, 2020 21:01 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 27,278 $0.98 $26,732.44
Disclosure

SEC source: 0001562180-20-003766 · primarydocument.xml · nonDerivative · entry 2

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2020 Filed May 19, 2020 21:01 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 2,722 $1.32 $3,593.04
Disclosure

SEC source: 0001562180-20-003766 · primarydocument.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,213

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 14, 2020 Filed May 14, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $0.98 $0.00
Disclosure

SEC source: 0001562180-20-003646 · primarydocument.xml · derivative · entry 11

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,278

Underlying: Common Stock · 20,000 shares

Expires 2026-01-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The shares subject to the option vest over a period of four years. 34,346 of the shares subject to the option vested on January 15, 2016 and the remainder vest at a rate of 1/36th per month commencing on January 15, 2017 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
May 14, 2020 Filed May 14, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 129 $34.53 $4,454.37
Disclosure

SEC source: 0001562180-20-003646 · primarydocument.xml · nonDerivative · entry 8

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,491

F6 · price: This transaction was executed in multiple trades at prices ranging from $34.28 to $34.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 14, 2020 Filed May 14, 2020 21:58 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 19,871 $34.18 $679,252.38
Disclosure

SEC source: 0001562180-20-003646 · primarydocument.xml · nonDerivative · entry 7

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,620

F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on March 23, 2020.

F5 · price: This transaction was executed in multiple trades at prices ranging from $33.52 to $34.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.